Acute pancreatitis
Conditions
Interventions
Pancreatic duct stent group:ERCP+pancreatic duct stent placement
Non-pancreatic duct stent group:ERCP
Sponsors
General Hosptal of NingXia Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years; 2.Onset time = 8 points or CRP >= 150 mg/L; 4.Meets the diagnostic criteria of acute biliary pancreatitis and acute cholangitis at the same time; 5.Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients who have previously undergone pancreatic surgery; 2.Pregnant or lactating women; 3.Acute development stage of chronic pancreatitis; 4.Patients with severe heart, lung, liver, kidney, or mental illness that affect the treatment effect of acute pancreatitis or cannot cooperate with the operator (heart function> grade III, acute myocardial infarction, chronic kidney disease creatinine clearance rate <40ml/min, chronic obstructive pulmonary disease requiring long-term oxygen therapy, Child-Pugh grade C liver function of chronic liver disease, immune disease or immunosuppressed state, and dying patients); 5.Patients who cannot tolerate ERCP for various reasons (e.g., contrast agent allergy, severe fundus esophageal varices; Upper gastrointestinal obstruction, ulceration, bleeding, etc.; Coagulation dysfunction or long-term oral anticoagulants); 6.Patients who need to take pancreatic toxic drugs (such as estrogen, azathioprine, mesalazine, morphine derivatives, prednisone, etc.) during the study period; 7.Patients with biliopancreatic system tumors affecting the therapeutic effect.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of infectious pancreatic necrosis;Inflammatory factors; | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of hospital stay;Daily visual analogue scale pain score changes;Dosage of pain medication;Incidence of new complications;Mortality rate;Daily changes in sequential organ failure test scores;Oral feeding time;Application time of anti-pancreatin drugs;Intensive care unit length of stay and underlying reasons;Expenses during treatment (within and outside the insurance);Changes in inspection index; | — |
Countries
China
Contacts
Public ContactWang Zuozheng
General Hosptal of NingXia Medical University
Outcome results
None listed